In The Spotlight

Myelodysplastic syndrome, which refers to a group of blood disorders, affects an estimated 60,000 people in the U.S. The abnormal or malignant precursor cells in the bone marrow proliferates resulting in a disordered and ineffective production of the myeloid lineage, which includes red blood cells, white blood cells and platelets in patients with myelodysplastic syndrome.

Shares of Satsuma Pharmaceuticals Inc. (STSA) have gained more than 45% over the past 1 month and trade around $6.

AnaptysBio Inc. (ANAB), a clinical-stage biotechnology company developing innovative immunology therapeutics, has a drug candidate targeting hidradenitis suppurativa in its pipeline.

Silk Road Medical Inc. (SILK), a medical device company, expects to turn in double-digit revenue growth this year too, thanks to growing adoption of TCAR.

Alignment Healthcare Inc. (ALHC), a tech-enabled Medicare Advantage company, which delivered a strong first quarter across all key financial metrics, is scheduled to release its second quarter financial results next month.